
|Articles|May 1, 2003
Combination agents target early, late stages of allergy
Author(s)Nancy Groves, Mark Silverberg, MD
Ophthalmic drops that combine immediate antihistamine relief with prophylactic care in the form of mast cell inhibition and eosinophil blockage are the mainstay of therapy for allergic conjunctivitis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears BVI’s FineVision HP trifocal IOL for the US market
2
Treating myopia today: US-focused treatments, challenges, and global insights
3
AAO 2025: A practice’s experience with connecting "the why," building community for techs
4
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
5